ITN085ST (PHARAOH) - A Phase I Trial of Autologous Regulatory T Cell Therapy for Autoimmune Hepatitis

Project: Research project

Description

STATEMENT OF WORK (SOW) ITN Clinical Trial: ITN085ST (PHARAOH) - A Phase I Trial of Autologous Regulatory T Cell Therapy for Autoimmune Hepatitis

The Subrecipient Investigator has been designated as Mechanistic Protocol Co-Chair for the above referenced Immune Tolerance Network Clinical Trial. As Mechanistic Protocol Co-Chair of this trial, they will have overall responsibility for the conduct of the mechanistic component of the study. The Mechanistic Protocol Co-Chair will also participant in regular SMT calls. The Mechanistic Protocol Co-Chair will work under the guidance of the Immune Tolerance Network members located at BRI, UC San Francisco, and Massachusetts General Hospital.
StatusFinished
Effective start/end date6/1/181/31/19

Funding

  • Benaroya Research Institute at Virginia Mason (FY18|TN297//5UM1AI109565-05)
  • National Institute of Allergy and Infectious Diseases (FY18|TN297//5UM1AI109565-05)

Fingerprint

Autoimmune Hepatitis
Immune Tolerance
Regulatory T-Lymphocytes
Cell- and Tissue-Based Therapy
Clinical Trials
San Francisco
General Hospitals
Research Personnel